Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Long-term rollover study of Tafinlar and/or Mekinist in pediatric patients
NL-OMON51275Phase 4Recruiting
- Sponsor
- Novartis
- Start
- Jan 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of dabrafenib + trametinib and trametinib in glioma and brain neoplasm, sponsored by Novartis. Primary endpoint: Long-term safety. Started Jan 2023; status: recruiting.
02
Drugs
dabrafenib + trametinibtrametinib
03
Conditions
gliomabrain neoplasm
Beyond the preview
Go deeper on NL-OMON51275.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON51275.